Chinese pharmaceutical company, YC HEC Changjiang Pharma was attacked by short-seller, Emerson Analytics, in April 2022. The main allegations concerned the precarious financial position of the YC HEC’s ultimate parent, SZ HEC. The short-seller claimed YC HEC had bought assets at inflated prices from its parent. It set a price target of HK$3.29/share, with downside of 30%. YC HEC did not respond to the report; its shares have risen more than 40% since its publication. The allegations against YC HEC are unproven.

Last updated May 2023

The information on this page has been compiled from publicly available sources. GMT Research Limited has not verified the information and does not warrant its accuracy. Any claims made or views expressed are not necessarily those of GMT Research Limited.